Altogether, these data suggest that inhibiting mTORC1 with rapamycin treatment improves targeted inhibitor therapy by targeting DTP melanomas that overexpress NR2F1 and decreases regrowth rates of MRD. Here, NR2F1 is linked to melanoma.